U
PETX

UBS’s Aratana Therapeutics, Inc. PETX Stock Holding History

UBS’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$17K Buy
1,700
+600
+55% +$7.28K ﹤0.01% 8233
2014
Q2 		$17K Buy
1,100
+286
+35% +$4.05K ﹤0.01% 8300
2014
Q1 		$15K Sell
814
-479
-37% -$9.6K ﹤0.01% 8475
2013
Q4 		$25K Sell
1,293
-411
-24% -$8.34K ﹤0.01% 7887
2013
Q3 		$28K Buy
+1,704
New +$17.9K ﹤0.01% 7641

Other funds holding PETX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's PETX Position: Q3 2014 in Review

UBS increased its Aratana Therapeutics, Inc. (PETX) stake by 55% in Q3 2014, buying an estimated $7.28K and bringing the position to 1,700 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #8233.

UBS first reported a position in PETX in Q3 2013 and has held it in 5 quarters since. The position peaked at $28K in Q3 2013. 82 funds tracked by Wall St. Rank hold PETX as of Q3 2014.

  • UBS held 1,700 shares of Aratana Therapeutics, Inc. worth $17K as of Q3 2014.
  • UBS bought 600 Aratana Therapeutics, Inc. shares in Q3 2014, an estimated $7.28K.
  • Aratana Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8233 holding.
  • UBS first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and has held it in 5 quarters since.
  • UBS's Aratana Therapeutics, Inc. position peaked at $28K in Q3 2013.
  • 82 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.